Amphastar Pharmaceuticals filings document the regulatory disclosures of a Delaware biopharmaceutical company focused on generic and proprietary injectable, inhalation, and intranasal products, along with active pharmaceutical ingredient products. Form 8-K reports furnish operating results, product revenue commentary, non-GAAP measures, and material business updates tied to the company's pharmaceutical products business.
Amphastar's SEC filings also cover governance and capital-structure matters, including proxy disclosures, executive compensation, employment agreements, equity-compensation dilution, and share repurchase authorizations. Material agreement filings describe licensing rights for a corticotropin compound, supply arrangements involving a Chinese subsidiary, related-party review procedures, and commercial terms that affect the company's pipeline, manufacturing, and distribution activities.
Insider sale notice for AMPH: This Form 144 shows a proposed sale of 500 shares of Amphastar Pharmaceuticals common stock through UBS Financial Services on or about 10/01/2025, with an aggregate market value listed as $13,370.00. The shares were originally acquired as RSUs on 06/07/2022. The filer previously sold three blocks of 500 shares each during July, August and September 2025, generating gross proceeds of $11,733.95, $10,415.75, and $15,491.65 respectively. The filing lists total shares outstanding as 46,495,077, indicating the planned sale is a small fraction of the company’s outstanding shares. The notice includes the signer’s representation that no undisclosed material adverse information about the issuer is known.
Amphastar Pharmaceuticals entered into a three-year contract research agreement with Nanjing Hanxin Pharmaceutical Technology effective September 15, 2025. Under this deal, Hanxin will develop Recombinant Peptide Research Cell Banks (RCBs) for Amphastar’s product candidate AMP-107 and license them under a fully paid, exclusive, perpetual, transferable, sub-licensable worldwide license.
All title to the RCBs and related development and manufacturing know-how, including engineering, scientific data, designs, and procedures, will belong to Amphastar. The total cost of the agreement will not exceed approximately $2.8 million, paid in Chinese yuan, including an initial payment of about $0.3 million on the effective date, with any extra work billed on a cost-plus basis subject to prior approval.
The filing notes this is a related-party transaction because Amphastar CEO Dr. Jack Zhang, COO and Chairman Dr. Mary Luo, and certain family members beneficially own a majority of Hanxin’s equity. The independent and disinterested members of the Audit Committee evaluated and approved Amphastar’s entry into the agreement.
Floyd F. Petersen, a director of Amphastar Pharmaceuticals (AMPH), sold 500 shares on 09/02/2025 under a pre-existing Rule 10b5-1 trading plan. The sales were executed at a weighted-average price of $30.9833 per share, with individual sale prices ranging from $30.60 to $31.225. Following the reported disposition, Petersen is recorded as beneficially owning 76,531 shares. The Form 4 was signed by Eva Wen by power of attorney on 09/03/2025.
Form 144 notice by Floyd Peterson for Amphastar Pharmaceuticals, Inc. (AMPH). The filer notifies a proposed sale of 500 shares of common stock through UBS Financial Services on NASDAQ with an approximate sale date of 09/02/2025 and an aggregate market value listed at $15,450.00. The shares were acquired as RSUs on 06/07/2022. The filing also discloses three sales by the same person in the past three months totaling 1,500 shares on 06/02/2025, 07/02/2025 and 08/01/2025 with combined gross proceeds of $34,984.75. The form includes the required representation that the seller is not aware of undisclosed material adverse information.
Amphastar Pharmaceuticals entered a license agreement with Nanjing Anji Biotechnology granting Amphastar exclusive rights in the United States and Canada to develop, make, use and commercialize products incorporating certain compounds, including three identified Licensed Products. Amphastar paid an $0.75 million earnest payment and a $5.25 million upfront fee on signing and agreed to up to $42 million in development milestones and up to $225 million in sales milestones, plus royalty payments capped at $22.5 million per product per year and a $60 million accumulated cap per product. Amphastar will share a percentage of sublicense income with Anji, and Anji will pay Amphastar royalties on net sales tied to Amphastar-licensed patents outside the Territory.
The agreement term runs product-by-product and region-by-region to the tenth anniversary of first commercial sale with an Amphastar option to extend up to ten additional years or until patent claims lapse. The company disclosed customary forward-looking statements and identified risks including regulatory approval, commercialization success, legal and regulatory changes, and supply-chain disruptions, and incorporated the full Agreement by reference to be filed as an exhibit.
Amphastar Pharmaceuticals (AMPH) – SEC Form 4
Director Floyd F. Petersen disclosed the sale of 500 common shares on 01 Aug 2025 at a weighted-average price of $20.8315. The transaction was executed under a Rule 10b5-1 trading plan adopted 26 Nov 2024, indicating it was pre-scheduled rather than discretionary. After the sale, Petersen directly owns 77,031 shares, so the disposition equals roughly 0.6 % of his stake and is immaterial relative to Amphastar’s total share count. No derivative securities activity or additional insider trades were reported.
The filing therefore conveys routine insider diversification without signaling a change in corporate fundamentals or outlook.